Risperdal vs. Vraylar
See how Risperdal and Vraylar compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Both drugs are atypical antipsychotics, but Risperdal is approved for schizophrenia, bipolar mania, and autism-related irritability, while Vraylar also covers bipolar depression and add-on therapy for major depressive disorder.
Risperdal has been available since 1993 and comes in a low-cost generic, while Vraylar has no generic version and typically costs several times more per month.
Vraylar has a long half-life, so dose changes take weeks to fully show their effect, while Risperdal reaches steady levels faster and comes in more formulations, including a liquid and a dissolving tablet.
Risperdal vs. Vraylar Drug Summary
Risperdal
Risperdal (risperidone) is an atypical antipsychotic available as a tablet, oral solution, or dissolving tablet, usually taken once or twice daily. It is FDA-approved for schizophrenia in adults and teens, manic or mixed episodes of bipolar I disorder, and irritability linked to autistic disorder in children. Dosing starts low and increases gradually to a typical maintenance range of 4 mg to 8 mg per day.
Vraylar
Vraylar (cariprazine) is an atypical antipsychotic capsule taken once daily, with or without food. It is FDA-approved for schizophrenia and bipolar I mania in adults, along with bipolar I depression and, as an add-on, major depressive disorder. Dosing starts low and rises slowly, since its long-acting metabolites take weeks to show their full effect.
Risperdal vs. Vraylar Side Effects
Risperdal
Vraylar
Risperdal vs. Vraylar Dosage
Risperdal
Vraylar
| STAGE | DOSE | WHEN |
| Starting dose | 2 mg once daily | Day 1 |
| Maximum dose | 2 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
| STAGE | DOSE | WHEN |
| Starting dose | 1.5 mg once daily | Day 1 |
| Maximum dose | 1.5 mg to 6 mg daily | Day 3 onward |
| Dose changes | 2 increases | Every day |
Risperdal
| STAGE | DOSE | WHEN |
| Starting dose | 2 mg once daily | Day 1 |
| Maximum dose | 2 mg once daily | Same as starting |
| Dose changes | None | Fixed dose |
Vraylar
| STAGE | DOSE | WHEN |
| Starting dose | 1.5 mg once daily | Day 1 |
| Maximum dose | 1.5 mg to 6 mg daily | Day 3 onward |
| Dose changes | 2 increases | Every day |
Risperdal vs. Vraylar Indications
Risperdal
Risperdal is FDA-approved for schizophrenia in adults and teens 13 and older, for manic or mixed episodes of bipolar I disorder, and for irritability tied to autistic disorder in children and teens. Doctors also prescribe it off-label for tic disorders like Tourette syndrome and to boost antidepressants in treatment-resistant OCD.
Schizophrenia (ages 13 and up)
Bipolar I manic or mixed episodes
Irritability from autistic disorder
Off-label: OCD augmentation, tics
Vraylar
Vraylar is FDA-approved for schizophrenia and manic or mixed episodes of bipolar I disorder in adults, plus depressive episodes of bipolar I disorder. It is also approved as an add-on to antidepressants for major depressive disorder, and for bipolar mania in children as young as 10.
Schizophrenia (adults)
Bipolar I manic or mixed episodes
Bipolar I depression (adults)
Add-on for major depressive disorder
Risperdal vs. Vraylar Pros and Cons
Risperdal
Risperdal has been on the market since 1993, giving decades of real-world safety data, and it is available as a low-cost generic in multiple forms. Like all antipsychotics it carries a boxed warning against use in elderly dementia-related psychosis, and it carries a comparatively high risk of prolactin-related side effects.
Pros
Available as an inexpensive generic
Comes in tablet, liquid, and dissolving-tablet forms
Long track record dating back to 1993
Cons
Higher risk of prolactin elevation than many newer antipsychotics
Parkinsonism and dizziness are common during titration
Not approved for elderly dementia-related psychosis (boxed warning)
Vraylar
Vraylar covers a wider mood-disorder range, including bipolar depression and add-on therapy for major depressive disorder, uses Risperdal does not have. It has no generic version yet, so out-of-pocket costs are far higher, and its long half-life means side effects and benefits can take weeks to fully appear.
Pros
FDA-approved for bipolar depression and MDD add-on therapy
Once-daily capsule with a simple titration schedule
Metabolic changes in lipids and blood sugar trend milder in trials
Cons
No generic version; roughly $1,300 to $1,900 per month without insurance
Akathisia can affect up to 20% of patients during bipolar mania treatment
Long half-life delays full effect of dose changes by several weeks
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.